How to buy Atara Biotherapeutics stock (ATRA)

Atara Biotherapeutics is a biotechnology business based in the US. Atara Biotherapeutics shares (ATRA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $12.15 – a decrease of 0.41% over the previous week. Atara Biotherapeutics employs 165 staff and has a trailing 12-month revenue of around $62.4 million.

Our top picks for where to buy Atara Biotherapeutics stock

Buy Atara Biotherapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Atara Biotherapeutics stock price (NASDAQ: ATRA)

Use our graph to track the performance of ATRA stocks over time.

Atara Biotherapeutics shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$12.15
52-week range	$6.50 - $39.50
50-day moving average more info button	$10.90
200-day moving average more info button	$11.68
Wall St. target price	$16.33
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-25.32

Is it a good time to buy Atara Biotherapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Atara Biotherapeutics price performance over time

Historical closes compared with the close of $12.15 from 2024-12-27

1 week (2024-12-23)	-0.41%
1 month (2024-11-29)	-0.21%
3 months (2024-09-30)	49.45%
6 months (2024-06-28)	42.94%

1 year (2023-12-29)	2,269.34%
2 years (2022-12-30)	-85.18%
3 years (2021-12-30)	403
5 years (2019-12-30)	402.25

Atara Biotherapeutics financials

Revenue TTM	$62.4 million
Gross profit TTM	$63.6 million
Return on assets TTM	-57.48%
Return on equity TTM	-2014.86%
Profit margin	-290.2%
Book value	$-23.31
Market Capitalization more info button	$76.8 million

TTM: trailing 12 months

Atara Biotherapeutics share dividends

We're not expecting Atara Biotherapeutics to pay a dividend over the next 12 months.

Have Atara Biotherapeutics's shares ever split?

Atara Biotherapeutics's shares were split on a 1:25 basis on 19 June 2024 . So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Atara Biotherapeutics shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Atara Biotherapeutics shares which in turn could have impacted Atara Biotherapeutics's share price.

Atara Biotherapeutics share price volatility

Over the last 12 months, Atara Biotherapeutics's shares have ranged in value from as little as $6.5 up to $39.5. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Atara Biotherapeutics's is 0.495. This would suggest that Atara Biotherapeutics's shares are less volatile than average (for this exchange).

Atara Biotherapeutics overview

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Frequently asked questions

null
What percentage of Atara Biotherapeutics is owned by insiders or institutions?
Currently 22.151% of Atara Biotherapeutics shares are held by insiders and 50.825% by institutions. How many people work for Atara Biotherapeutics?
Latest data suggests 165 work at Atara Biotherapeutics. When does the fiscal year end for Atara Biotherapeutics?
Atara Biotherapeutics's fiscal year ends in December. Where is Atara Biotherapeutics based?
Atara Biotherapeutics's address is: 2380 Conejo Spectrum Street, Thousand Oaks, CA, United States, 91320 What is Atara Biotherapeutics's ISIN number?
Atara Biotherapeutics's international securities identification number is: US0465131078 What is Atara Biotherapeutics's CUSIP number?
Atara Biotherapeutics's Committee on Uniform Securities Identification Procedures number is: 046513107